logo
Share SHARE
FONT-SIZE Plus   Neg

AstraZeneca Says US District Court Finds SEROQUEL XR Formulation Patent As Valid

AstraZeneca Plc (AZN,AZN.L) said Thursday that the US District Court for the District of New Jersey has found the formulation patent protecting SEROQUEL XR (quetiapine fumarate) extended release tablets to be valid.

According to the company, the court has ruled that Anchen Pharmaceuticals Inc., Osmotica Pharmaceutical Corp., Torrent Pharmaceuticals Limited, Torrent Pharma Inc., Mylan Pharmaceuticals Inc., and Mylan Inc. (MYL) have infringed the SEROQUEL XR formulation patent. The SEROQUEL XR formulation patent expires in 2017.

The decision follows a ruling made in the UK on March 22, 2012, which found the formulation patent protecting SEROQUEL XR to be invalid. In the Netherlands, however, on March 7, 2012, the District Court in The Hague found the formulation patent protecting SEROQUEL XR to be valid.

AstraZeneca said it is pleased with the US District Court's decision, which the company believes underlines the strength of its patents.

Seroquel generated $5.83 billion in global sales last year, with $1.4 billion coming from Seroquel XR.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Even after two years of thoroughly searching across the Indian Ocean, using modern technologies and devices, there is no clue about the Malaysian airline that vanished on March 8, 2014. Internet access is growing worldwide, but there is still a long way to go before the entire world is completely wired, a study from the Pew Research Center has found. The study also noted that men have greater access to the Internet than women in many nations. Backtracking on its early announcements on digital privacy, WhatsApp is planning to share member information, phone numbers and analytical data with Facebook, to make revenue from the platform.
comments powered by Disqus
Follow RTT